Decoy-Resistant Interleukin-18 (DR-18) for Relapse or Pre-emptive Treatment of Measurable Residual Disease After Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome (DR. DREAM)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 30 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vevoctadekin (Primary)
Indications Acute myeloid leukaemia; Myelodysplastic syndromes
Focus Adverse reactions
Acronyms DR. DREAM Trial

Most Recent Events

10 Dec 2024 Trial design presented at the 66th American Society of Hematology Annual Meeting and Exposition.
05 Dec 2024 According to a Simcha Therapeutics media release, data from this study will be presented at ASH.
05 Dec 2024 According to a Simcha Therapeutics media release, the company announced the opening of this trial assessing the use of ST-067.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight